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SUMMARY
BACKGROUND—In high tuberculosis (TB) burden, resource-poor countries, sputum smear
microscopy remains the mainstay of diagnosis. The low sensitivity of this test means that patients
with smear-negative but culture-positive TB pass undetected through the health care system. Such
clinical episodes are missed opportunities for diagnosis and interruption of transmission, which
might be averted through the application of more sensitive diagnostic tests.
OBJECTIVES—To estimate the proportion of incident TB cases that might have been detected
earlier than the actual date of diagnosis if a test more sensitive than smear microscopy had been
used at an earlier presentation episode.
METHOD—Retrospective cohort study in urban Peru, investigating health care facility
interactions for symptoms suggestive of TB prior to TB diagnosis through patient interviews and a
review of clinical records.
RESULTS—Of 212 participants enrolled, 58% had one or more clinical interactions prior to their
diagnostic episode. Of those with a prior episode, the median number of episodes was three. The
median delay to diagnosis from first presentation was 26 days.
CONCLUSION—There are clear missed opportunities for earlier TB diagnosis, delaying
treatment initiation and continued spread of Mycobacterium tuberculosis to the community. The
implementation of sensitive diagnostic tests appropriate to resource-poor settings should be given
high priority.
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FOR THE MAJORITY of tuberculosis (TB) suspects around the world, the only diagnostic
test available is sputum smear microscopy.1 Although inexpensive and relatively
straightforward, this 100-year-old method fails to detect at least half of cases identified by
sputum culture.2–6 As a result, patients with smear-negative but culture-positive TB pass
undetected through health care systems where smear microscopy is the only diagnostic
modality available, and are told incorrectly that they do not have TB. Some, but presumably
not all, find their way back to the clinic when their disease has advanced sufficiently to be
detectable by smear microscopy. In the interim, such individuals will have accrued greater
morbidity and will have continued transmitting Mycobacterium tuberculosis to their
contacts.7 These initial clinical episodes are therefore missed opportunities for earlier
diagnosis, treatment and interruption of transmission, which may be avoidable through the
application of more sensitive diagnostic tests.
New diagnostic tests suitable for use in resource-poor settings are available.8,9 Liquid
culture was recommended in 2007 by the World Health Organization (WHO) for wider
implementation in global TB control, as it is faster and more sensitive than solid media
culture and can reliably determine drug susceptibility.10,11 Manual Mycobacteria Growth
Indicator Tube (MGIT) and microscopic observation drug susceptibility assay (MODS) are
sensitive assays with fewer technical and economic constraints than automated platforms.
12,13
However, the extent of the potential impact of even a highly sensitive low-cost test depends
on the frequency of the opportunities missed for diagnosis. If, in reality, a high proportion of
diagnosed TB patients have positive sputum smear results on first presentation to a health
facility, there is little room for improvement regardless of the superiority of a new test.
Consideration of the frequency of opportunities missed for earlier diagnosis may therefore
be at least as important as the sensitivity of the test.
The present study aimed to determine the proportion of incident cases of microbiologically
confirmed (smear-positive or culture-positive) pulmonary TB that might have been detected
earlier than the actual date of diagnosis if a test more sensitive than smear microscopy had
been used at an earlier presentation. The specific outcomes of interest were the proportion of
TB patients with at least one clinical interaction prior to their diagnostic episode (and
therefore at least one missed opportunity for diagnosis), and within this group the time delay
incurred from the first clinical episode to diagnosis.
METHODS
Setting
This retrospective cohort study was undertaken in the adjacent districts of San Juan de
Miraflores and Villa María del Triunfo, a high TB burden region in south Lima, Peru (TB
incidence 150 per 100 000 in 2006), with an estimated adult human immunodeficiency virus
(HIV) prevalence rate of 0.5% and HIV prevalence in incident TB cases of 6.7%.14,15
Study population
Study subjects were current adult TB patients (aged ≥18 years) who had been diagnosed
with microbiologically confirmed (acid-fast bacilli smear or Ogawa culture-positive)
pulmonary TB within the previous 6 months and who were receiving treatment under the
National TB Programme (NTP).
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Study procedures
All NTP clinical facilities in the study districts were visited to identify potential participants
from the TB register of current patients. Patients meeting the study criteria were invited to
participate and were provided with an information sheet describing the study and their
potential involvement. Each participant was required to give written informed consent.
Participants were interviewed either in the clinical facilities where they received treatment
or, when this was not possible, in their homes. A complete history of clinic visits and
sputum sample submission was obtained from a semi-structured interview with each
participant; relevant TB control programme and clinical and laboratory workbooks were
reviewed to identify confirmatory information for each participating patient. When
documentation was available, dates and outcomes of the interactions were abstracted using a
standardised data collection form, including information from distant and private health
facilities, if relevant.
To calculate the number of prior clinical episodes and the subsequent delay to final
diagnosis, it was necessary to consolidate several sources of data. Thus, as data abstracted
from written records did not always correspond to the information reported by the patients,
the following hierarchical approach was taken. The date of TB diagnosis was taken as the
recorded date of the initial positive microbiological result. The information from a written
record of an episode was used unless this information was either missing or inaccessible, in
which case the participant’s estimate was used. If a participant could only recall a date down
to the month and not the day, the 15th day of the month was assigned.
Definitions
Information was obtained on health care episodes in the 12 months prior to TB diagnosis.
An episode was defined as any clinical interaction at a public or private health care
establishment that included consultation with a physician or TB nurse, or the independent
submission of sputum specimens for TB smear microscopy unrelated to a clinic visit. It is
not uncommon for patients to submit sputum samples for testing directly to their local health
centre (which is free), rather than to first consult with a health professional (which entails a
nominal fee). The submission of two sputum samples was considered as one episode, as per
local guidelines for sputum collection. When submission of one or two sputum samples
occurred in conjunction with a clinic visit, all were defined as one episode. On occasions
when patients continued to submit further specimens (usually to avoid paying for additional
consultations) each successive two specimens were counted as a separate episode. The
rationale for this was twofold: the local guidelines for the diagnosis of TB recommend the
submission of two specimens per visit, and subsequent pairs of samples were almost never
submitted within the same week, and thus represented temporally discrete additional
opportunities for diagnosis. Episodes for reasons other than potential TB, or when TB was
not considered by the attending health practitioner (based on clinical record review or
patient interview), were not included. Each episode was classified as follows: 1) TB
considered but sputum smear result not available; 2) TB considered and sputum smear result
available. Reasons for which no smear result was available include: a specimen was not
requested, the patient was unable or unwilling to produce sputum, and the specimen or the
result was lost.
Data entry and analysis
Data were double-entered and analysed in an Access (MS) database (Microsoft, Redmonds,
WA, USA). The frequency distribution of prior clinical episodes over time was determined
and routine summary statistics were calculated. Proportions were compared by χ2 using Epi
Info 6.4 (Centers for Disease Control and Prevention, Atlanta, GA, USA).
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Ethics
Ethics approval was granted by the Institutional Review Board of the Universidad Peruana
Cayetano Heredia. Permission to conduct the study within the Lima Sur region was granted
from the regional health department (Dirección de Salud Lima Sur), and local permission
from each health facility visited was obtained on arrival.
RESULTS
Study population
Of 424 TB patients identified, microbiological confirmation was lacking for 96 (22.6%),
leaving 328 (77.4%) potential participants, of whom 212 (50.0%) were located and enrolled.
It was not possible to locate 113 (26.6%) eligible participants; a further three declined the
invitation to participate; 43.4% of those who participated were female. The overall median
age was 30 years (range 18–86). The median time since diagnosis was 86.4 days
(interquartile range [IQR] 46.8–132.3).
Diagnostic profile
The majority of the patients included in this study (96.2%) were diagnosed by positive
sputum smear microscopy; eight (3.8%) had a positive sputum culture and negative smear.
Symptom profile at the time of diagnosis was generally similar for patients diagnosed at
their first visit and those diagnosed after more than 1 visit. Among the 118 patients with
multiple episodes, only three symptoms, cough for at least 2 weeks, sputum production and
weight loss, were significantly more frequent at the time of diagnosis than at earlier visits
(Table).
Diagnostic delay
The 212 participants had a total of 426 clinical episodes: 89 (42.0%) were diagnosed on first
presentation, 60 (28.3%) had two episodes, 41 (19.3%) had three, 18 (8.5%) had four, 2
(0.9%) had five and 2 (0.9%) had six episodes. For the 58.0% of patients with at least one
prior clinical episode, the diagnostic visit occurred a median of 26 days after their first
episode (IQR 6–61.5 days). All participants with prior episodes had at least one negative
smear result from one of the prior non-diagnostic episodes.
Missed opportunities
The frequency distribution of episodes failing to result in a diagnosis of TB (missed
opportunities) in the 12 months prior to microbiologically confirmed diagnosis is shown in
Figure 1. The cumulative proportion of all these episodes, going backward in time, is shown
by the curve.
Of the 214 non-diagnostic episodes, 126 occurred during the month prior to diagnosis. The
distribution of episodes is shown by available and unavailable smear result. A smear result
was not available in 53% of the prior clinical episodes. It can be seen that 76.2% of missed
opportunities occurred within the 2-month period prior to diagnosis. Within 3, 4, 6 or 10
months, respectively 83.6%, 92.1%, 93.9% and 98.1% of missed opportunities occurred
prior to positive smear-based diagnosis. The temporal distribution of the first and subsequent
missed opportunities for each participant is shown in Figure 2.
DISCUSSION
The premise for this study was that patients with TB frequently pass through the health care
system more than once on their journey to a TB diagnosis, but the frequency and temporal
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relation to eventual diagnosis has not been previously described. These data demonstrate
that over half of TB patients had prior interactions with clinical services that might represent
missed opportunities for diagnosis. Although half of these episodes occurred in the 26 days
preceding diagnosis, the remainder occurred over many months. These prolonged periods of
undiagnosed disease likely result in increased morbidity and increased household and
community transmission.
To what extent are these missed diagnostic opportunities avoidable with the new diagnostic
tools that are becoming available? The potential incremental benefit of new diagnostic tool
implementation depends upon sensitivity of detection and how frequently that additional
sensitivity is needed. At first glance it appears that sputum smear microscopy performs well:
71% of patients were diagnosed either at their first visit (42%) or within the subsequent 26
days (29%); however, this leaves the long tail of 29% of eventually smear-positive cases that
are missed.
An important assumption underlying the conclusions of this study is that when TB patients
presented to health care services prior to the episode at which the diagnosis was made, they
had active TB that would have been detected if they had undergone testing by a more
sensitive tool. This requires that 1) TB is considered in the differential and a sample taken
for testing; and 2) the patient does indeed have active TB detectable by, for example,
culture. As this was a retrospective study, samples from previous non-diagnostic episodes
were no longer available. Study results were therefore analysed under two scenarios: those
that generated an available smear result and those that did not.
In this study, all patients with at least one episode prior to their diagnostic episode had an
interaction that generated a negative sputum smear result, although in just over half of the
prior episodes reported, a sputum smear result was unavailable. While it may be argued that
episodes without a sputum smear are not missed opportunities—as an improved diagnostic
tool is of no use without a specimen—it might also be the case that a more sensitive, rapid
diagnostic might influence clinician practice, and thus the proportion of interactions that
generate a specimen.
Even if all patients had been tested at every previous clinical interaction, they would not
necessarily all have had smear-negative, culture-positive TB at every prior episode.
However, the utility of the cumulative frequency percentage curve for missed opportunities
in Figure 1 is that the cumulative proportion of missed opportunities that might have
resulted in detectable disease at an earlier timepoint can be derived, depending upon the
duration selected. Similarly, the cumulative proportion of patients at their first episode that
might have been detectable at an earlier timepoint can be derived from Figure 2. The
detection of cases at earlier timepoints depends both upon the natural history of smear-
positive TB and upon the sensitivity of the test. Although test performance, which affects
the sensitivity of smear microscopy, was not directly evaluated in this retrospective study,
all laboratories in the NTP network conduct ongoing smear quality control and participate in
the National Reference Laboratory external quality assessment programme, and there is no
reason to believe that performance was substandard. We thus believe these data to be
generalisable.15
Information from the interviews was corroborated with recorded data. In practice, data
verification was incomplete, as records were often missing and documentation was patchy,
thus a hierarchical approach to consolidate the data was developed. Studies relying on
record review will invariably miss the full picture, especially where no single provider
oversees the care of an individual. Although participant recall bias is a concern, patients
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themselves are assumed to provide more comprehensive and complete information than can
be found in the records alone.
A possible bias in the results relates to the eligible non-participants who could not be
located. This group almost exclusively fell into two categories: those whose time at the
clinic or home was minimal due to work and those who had given a false address. Trying to
locate patients at their place of work was considered inappropriate on ethical grounds.
Enrolled subjects consisted of those employed and unemployed, as well as retired people,
students and homemakers. It is not known whether these missing participants would
contribute different or similar results.
As only patients with microbiologically confirmed TB were included in this study, the
analysis does not take into account the experience of patients with smear-negative disease
started on TB treatment based on clinical or radiographic criteria. While they do not
contribute to the extent of missed opportunities identified in this study, this subgroup of
patients, which formed nearly a quarter of all potential participants, likely represents further
opportunities for a more sensitive test to provide earlier diagnosis.
While this is the first study to identify and quantify specific missed opportunities for
diagnosis using current diagnostic algorithms in Peru, the urgent need for more accurate,
affordable tools to diagnose and control TB is well recognised.16 A recently published
systematic review of delay in the diagnosis and treatment of TB found that negative sputum
smear was significantly associated with diagnostic delay.17 A cross-sectional study of
diagnostic and treatment delay among pulmonary TB patients in Ethiopia found a median
delay from the first health provider visit to initiation of treatment of 61 days, although the
frequency or timing of visits was not reported.18 The frequency of missed diagnostic
opportunities is at least as important as test sensitivity for improving diagnoses. If this study
had demonstrated that missed diagnostic opportunities were uncommon, the implementation
of even a highly sensitive test would have been unlikely to deliver sufficient incremental
benefit to warrant usage. However, these data clearly show that there is a need for wider use
of more sensitive diagnostics to bridge this diagnostic gap. Such tests should also deliver
rapid results—rapid liquid culture methods satisfy the requirements for increased sensitivity
and speed.
CONCLUSION
There are clear opportunities missed for the diagnosis of tuberculosis, resulting in a delay in
treatment for patients and the continued spread of M. tuberculosis in the community. The
implementation of sensitive diagnostic tests relevant to the resource-poor setting must be a
priority.
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Figure 1.
Distribution of missed opportunities in the 12 months preceding diagnosis for participants
with at least one prior non-diagnostic episode.
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Figure 2.
Temporal distribution of first and subsequent missed opportunity episodes. The cumulative
proportion of first episodes is shown. If all participants had been diagnosed on first
presentation, this curve also represents the cumulative proportion of earlier diagnoses at any
given time point. Thus, 56.1% of those with a delay in diagnosis would have been diagnosed
within the 1 month prior to their diagnosis, and 74.8% within the preceding 2 months. The
grey line shows the cumulative proportion for the first episodes of the total cohort, including
the 89 who were diagnosed on first presentation. Again assuming TB had been detected on
the first presentation of all participants, 32.6% of the total cohort would have been
diagnosed up to 1 month earlier. At 2, 6 or 10 months prior to positive smear-based
diagnosis, 43.4%, 53.8% or 56.6% of all participants would have been detected earlier.
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Table
Reported symptom profile at diagnosis and at earlier non-diagnostic clinical episodes
Diagnosed following
repeated episodes
Symptom
Diagnosed
at first
episode
(n = 94)
%
At
diagnosis
(n = 118)
%
At episodes
prior to
diagnosis
(n = 203)
%
P value*
Cough ≥2 weeks 91.5 92.4 84.7 0.05
Sputum production 84.0 77.1 65.0 0.02
Fever 64.9 55.9 48.3 0.19
Haemoptysis 33.0 41.5 35.5 0.28
Weight loss 84.0 81.4 70.0 0.02
Night sweats 68.1 60.2 50.2 0.08
Chest pain 72.3 74.6 68.5 0.25
Breathlessness 59.6 63.6 57.1 0.26
*χ2 comparison of ‘at diagnosis’ vs. ‘prior to diagnosis’. There were no statistically significant differences between ‘diagnosed at first episode’ and
‘at diagnosis’ for those with repeated episodes.
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